NCT06445374View on ClinicalTrials.gov

Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing Immunotherapy or Oral Challenges

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 15, 2024

Primary Completion Date

April 8, 2025

Study Completion Date

April 8, 2025

Conditions

HypersensitivityAnaphylaxis

Interventions

DRUG

Inhaled Epinephrine

"0.125 mg per inhalation.~The maximum proposed dose to be administered is 1.0 mg (consisting of 8 inhalations of 0.125 mg over 6 minutes)."

Trial Locations (1)

V7C 5L9

1232176 Bc Ltd, Richmond

All Listed Sponsors

lead

Dr. George Luciuk

OTHER

NCT06445374 - Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing Immunotherapy or Oral Challenges | Biotech Hunter | Biotech Hunter